Antipsychotic use in children and adolescents: a 1-year follow-up study.

Baeza I, de la Serna E, Calvo-Escalona R, Morer A, Merchán-Naranjo J, Tapia C, et al.. Antipsychotic use in children and adolescents: a 1-year follow-up study. J Clin Psychopharmacol. 2014;34(5):613-9. DOI: 10.1097/JCP.0000000000000190. PubMed PMID: 25154009.

Antipsychotic polypharmacy in children and adolescents at discharge from psychiatric hospitalization.

Saldaña SN, Keeshin BR, Wehry AM, Blom TJ, Sorter MT, DelBello MP, et al.. Antipsychotic polypharmacy in children and adolescents at discharge from psychiatric hospitalization. Pharmacotherapy. 2014;34(8):836-44. DOI: 10.1002/phar.1453. PubMed PMID: 24990538.

A systematic review of treatments for refractory depression in older people.

Cooper C, Katona C, Lyketsos K, Blazer D, Brodaty H, Rabins P, et al. A systematic review of treatments for refractory depression in older people. Am J Psychiatry. 2011;168(7):681-8. DOI: 10.1176/appi.ajp.2011.10081165. PubMed PMID: 21454919.

Journal of Child and Adolescent Psychopharmacology. From the editor-in-chief's desk.

Koplewicz HS. Journal of Child and Adolescent Psychopharmacology. From the editor-in-chief's desk. J Child Adolesc Psychopharmacol. 2014;24(5):237. DOI: 10.1089/cap.2014.2451. PubMed PMID: 24945084.

Factors associated with antipsychotic polypharmacy and high-dose antipsychotics among individuals receiving compulsory treatment in the community.

Gisev N, Bell JS, Chen TF. Factors associated with antipsychotic polypharmacy and high-dose antipsychotics among individuals receiving compulsory treatment in the community. J Clin Psychopharmacol. 2014;34(3):307-12. DOI: 10.1097/JCP.0000000000000098. PubMed PMID: 24717256.

When is antipsychotic polypharmacy supported by research evidence? Implications for QI.

Gören JL, Parks JJ, Ghinassi FA, Milton CG, Oldham JM, Hernandez P, et al.. When is antipsychotic polypharmacy supported by research evidence? Implications for QI. Jt Comm J Qual Patient Saf. 2008;34(10):571-82. PubMed PMID: 18947117.

Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials.

Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull. 2009;35(2):443-57. DOI: 10.1093/schbul/sbn018. PubMed PMID: 18417466.

Side effects from use of one or more psychiatric medications in a population-based sample of children and adolescents.

Hilt RJ, Chaudhari M, Bell JF, Wolf C, Koprowicz K, King BH. Side effects from use of one or more psychiatric medications in a population-based sample of children and adolescents. J Child Adolesc Psychopharmacol. 2014;24(2):83-9. DOI: 10.1089/cap.2013.0036. PubMed PMID: 24506790.

Problems of polypharmacy.

Herxheimer A, McGettigan P. Problems of polypharmacy. BMJ. 2013;347:f7500. DOI: 10.1136/bmj.f7500. PubMed PMID: 24366533.

Add clinical indications to prescription instructions to avoid problems of polypharmacy.

Masters NJ. Add clinical indications to prescription instructions to avoid problems of polypharmacy. BMJ. 2013;347:f7496. DOI: 10.1136/bmj.f7496. PubMed PMID: 24366617.